C19 Treatments

Proxalutamide reduces COVID-19 mortality risk by 92 percent

By Hannah Balfour (European Pharmaceutical Review) In a Phase III trial, Proxalutamide reduced mortality and expedited recovery of hospitalised COVID-19 patients in Brazil. In a clinical trial, Proxalutamide reduced COVID-19 mortality risk by 92 percent and shortened the median hospital stay of patients by nine days. The investigator-initiated trial (NCT04728802), conducted by Dr Andy Goren and Dr …

Proxalutamide reduces COVID-19 mortality risk by 92 percent Read More »

Vitamin D (calcifediol) can ‘reduce Covid deaths by up to 60%

Research, published by the Social Science Research Network, found Covid-19 patients given doses of Vitamin D were 80 per cent less likely to require ICU treatment.  Those from the University of Barcelona also concluded that ‘adjusted results showed a reduced mortality of more than 60 per cent’ for those who were given the calcifediol treatment.  The …

Vitamin D (calcifediol) can ‘reduce Covid deaths by up to 60% Read More »

Discussion of meta-analysis & evidence to decision framework by Dr Tess Lawrie

Discussion with Dr Tess Lawrie about her META-ANALYSIS OF IVERMECTIN & EVIDENCE TO DECISION FRAMEWORK De Tess Lawrie has an MD & PhD. She grew up & studied medicine & received her PhD in South Africa, where she practised clinical medicine & surgery. She is founder & director of the Evidence Based Medical Consultancy in …

Discussion of meta-analysis & evidence to decision framework by Dr Tess Lawrie Read More »

tablets, medicine, supplement

Good news on Ivermectin for treatment of Covid-19

Press Release 6 January 2021New British research has examined and pooled data from a wide range of international studies–including Argentina, Bangladesh, Iran, Pakistan, Spain, Egypt, Indiaand the US –and found that the anti-parasitic medicine Ivermectin not only reduces deaths from Covid-19, but can be used to protect doctorsand nurses–as well as others who have had …

Good news on Ivermectin for treatment of Covid-19 Read More »

Scroll to Top